Table 4.
Patient and tumor characteristics of those who underwent CLND vs no CLND
| Characteristic | CLND (n = 10) n (%)a |
Non CLND (n = 9) n (%)a |
P value |
|---|---|---|---|
| Age at diagnosis (years) | 0.043 | ||
| Mean (SD) | 15 (2.83) | 11.11 (4.14) | |
| Median (range) | 14 (11, 21) | 13 (2, 15) | |
| Sex | > 0.99 | ||
| Female | 4 (40%) | 3 (33%) | |
| Male | 6 (60%) | 6 (67%) | |
| Primary tumor location | 0.18 | ||
| Extremity | – | 3 (33%) | |
| Head or neck | 3 (30%) | 1 (11%) | |
| Trunk | 7 (70%) | 5 (56%) | |
| Depth (mm) | 0.97 | ||
| Mean (SD) | 4.08 (3.04) | 3.38 (1.63) | |
| Median (range) | 2.63 (1.3, 9.4) | 3.5 (1.55, 7) | |
| Tumor depth | 0.62 | ||
| T1 | – | – | |
| T2 (1.01–2.00 mm) | 4 (40%) | 3 (33%) | |
| T3 (2.01–4.00 mm) | 2 (20%) | 4 (44%) | |
| T4 (> 4.00 mm) | 4 (40%) | 2 (22%) | |
| Ulceration | 0.023 | ||
| Yes | 8 (80%) | 2 (22%) | |
| No | 2 (20%) | 7 (78%) | |
| Mitosis | 0.47 | ||
| Absence | – | 1 (11%) | |
| Presence | 10 (100%) | 8 (89%) | |
| Mitotic counts | 0.15 | ||
| Mean | 8.7 (7.56) | 4.67 (4.21) | |
| Median | 6.5 (2, 26) | 3 (0, 13) | |
| Margin statusb | 0.78 | ||
| 1–5 mm | 4 (40%) | 3 (33%) | |
| 5–10 mm | 1 (10%) | 1 (11%) | |
| > 10 mm | 3 (30%) | 1 (11%) | |
| Free | 2 (20%) | 4 (44%) | |
| Adjuvant treatmentc | 0.21 | ||
| Yes | 10 (100%) | 7 (78%) | |
| No | – | 2 (22%) | |
| Median number (range) of SLN identified per patient | 3 (1, 7) | 3 (1, 4) | 0.79 |
CM conventional melanoma, SD standard deviation, mm millimeter, SLN sentinel lymph node
aValues indicate the number of patients (%), unless otherwise indicated
bMargin status indicates the size of the resection margin
cAdjuvant treatment included interferon alpha or immunotherapy